Oryzon Genomics SA
F:ORN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Oryzon Genomics SA
F:ORN
|
ES |
|
A
|
Arnoldo Mondadori Editore SpA
MIL:MN
|
IT |
|
MAP Aktif Adiperkasa Tbk PT
IDX:MAPA
|
ID |
|
Evome Medical Technologies Inc
XTSX:EVMT
|
US |
|
Agora Inc
NASDAQ:API
|
US |
|
A
|
Aurelia Metals Ltd
F:YTR
|
AU |
|
Partners Group Holding AG
OTC:PGPHF
|
CH |
|
M
|
Mineralbrunnen Ueberkingen-Teinach GmbH & Co KgaA
SWB:MUT
|
DE |
Intrinsic Value
Is ORN undervalued or overvalued?
See the intrinsic value estimate for 
Oryzon Genomics SA and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
ORN looks overvalued.
But is it expensive by its own standards?
See how today’s valuation compares with ORN’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What Oryzon Genomics Does
Oryzon Genomics is a drug development company focused on medicines that change how genes are switched on and off. Its main work is discovering and testing epigenetic drugs, especially compounds that block LSD1, an enzyme involved in cancer and some brain disorders. The company does not sell everyday consumer products; it builds drug candidates that may eventually be licensed or sold as prescription medicines if they win approval.
- Headquarters
- Spain ES
- Employees
- 46
- IPO date
- Dec 10, 2015
Earnings Waterfall
Oryzon Genomics SA
The intrinsic value for Oryzon Genomics SA (ORN) under the Base Case is hidden EUR.
Compared with the current market price of 2.538 EUR, the stock appears hidden.